Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 5 buys in history.
Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Skye Bioscience, Inc. | 8,393,520 | reported | 13 Mar 2024 | tx 1+450,000 |
| Entrada Therapeutics, Inc. | 2,963,066 | reported | 14 Nov 2025 | tx 25+4,163,694−4,179,224 |
| 5:01 Acquisition Corp. | 1,944,068 | reported | 30 Nov 2020 | tx 5+365,126−355,932 |
| IMPEL NEUROPHARMA INC | 1,348,524 | reported | 27 Apr 2021 | tx 11+2,884,791−37,517,590.28 |
| Q32 Bio Inc. | 18,000 | reported | 15 Jun 2022 | tx 23+10,884,814−7,578,194 |
| Vor Biopharma Inc. | 16,911 | reported | 14 Jun 2022 | tx 12+6,726,240−83,792,242 |
| Rallybio Corp | 16,500 | reported | 15 May 2024 | tx 21+4,292,828−23,326,350 |
| Audentes Therapeutics, Inc. | 10,000 | reported | 08 Jun 2018 | tx 3+37,000 |
| scPharmaceuticals Inc. | 6,124 | reported | 19 Jun 2018 | tx 1+6,124 |
| ARVINAS, INC. | 1,775 | reported | 24 Sept 2019 | tx 3+16,398−1,700 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 14 Nov 2025 | SALE | Entrada Therapeutics, Inc. | 200,000 | 8.80 USD | |
| 09 Jul 2025 | SALE | Entrada Therapeutics, Inc. | 20,065 | 7.50 USD | |
| 09 Jul 2025 | SALE | Entrada Therapeutics, Inc. | 6,935 | 7.50 USD | |
| 27 Jun 2025 | SALE | Entrada Therapeutics, Inc. | 19,265 | 6.91 USD | |
| 01 Jul 2025 | SALE | Entrada Therapeutics, Inc. | 6,422 | 7.12 USD | |
| 01 Jul 2025 | SALE | Entrada Therapeutics, Inc. | 18,578 | 7.12 USD | |
| 30 Jun 2025 | SALE | Entrada Therapeutics, Inc. | 6,422 | 6.81 USD | |
| 30 Jun 2025 | SALE | Entrada Therapeutics, Inc. | 18,578 | 6.81 USD | |
| 27 Jun 2025 | SALE | Entrada Therapeutics, Inc. | 55,735 | 6.91 USD | |
| 11 Jun 2025 | GRANT_AWARD | Entrada Therapeutics, Inc. | 19,000 | 0.00 USD | deriv |
| 13 Jun 2024 | GRANT_AWARD | Entrada Therapeutics, Inc. | 16,000 | 0.00 USD | deriv |
| 15 May 2024 | GRANT_AWARD | Rallybio Corp | 16,500 | 0.00 USD | deriv |
| 13 Mar 2024 | PURCHASE | Skye Bioscience, Inc. | 450,000 | 10.00 USD | first after silence |
| 02 Jan 2024 | GRANT_AWARD | Rallybio Corp | 27,118 | 1.77 USD | deriv |
| 08 Jun 2023 | GRANT_AWARD | Entrada Therapeutics, Inc. | 16,000 | 0.00 USD | deriv |
| 17 May 2023 | GRANT_AWARD | Rallybio Corp | 15,490 | 0.00 USD | deriv |
| 07 Mar 2023 | SALE | Rallybio Corp | 100,000 | 8.20 USD | |
| 03 Jan 2023 | GRANT_AWARD | Rallybio Corp | 10,344 | 0.00 USD | deriv |
| 30 Nov 2022 | TENDER | Akouos, Inc. | 982,453 | — | |
| 30 Nov 2022 | TENDER | Akouos, Inc. | 3,153,333 | — | |
| 01 Dec 2022 | OTHER | Akouos, Inc. | 16,000 | — | deriv |
| 23 Jun 2022 | GRANT_AWARD | Akouos, Inc. | 16,000 | 0.00 USD | deriv |
| 15 Jun 2022 | GRANT_AWARD | Q32 Bio Inc. | 18,000 | 0.00 USD | deriv |
| 14 Jun 2022 | GRANT_AWARD | Vor Biopharma Inc. | 16,911 | 0.00 USD | deriv |
| 03 Jun 2022 | SALE | Rallybio Corp | 99,671 | 12.50 USD |
1 purchase reported after at least 12 months of silence — most recent on 13 Mar 2024.